[go: up one dir, main page]

AR114926A1 - Derivados de azaindol como inhibidores de rho-quinasa - Google Patents

Derivados de azaindol como inhibidores de rho-quinasa

Info

Publication number
AR114926A1
AR114926A1 ARP190101592A ARP190101592A AR114926A1 AR 114926 A1 AR114926 A1 AR 114926A1 AR P190101592 A ARP190101592 A AR P190101592A AR P190101592 A ARP190101592 A AR P190101592A AR 114926 A1 AR114926 A1 AR 114926A1
Authority
AR
Argentina
Prior art keywords
alkyl
group
integer
independently
hydroxyalkyl
Prior art date
Application number
ARP190101592A
Other languages
English (en)
Inventor
Christine Edwards
David Edward Clark
Fabio Rancati
Alessandro Accetta
Original Assignee
Chiesi Farm Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiesi Farm Spa filed Critical Chiesi Farm Spa
Publication of AR114926A1 publication Critical patent/AR114926A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Reivindicación 1: Compuestos caracterizados porque son de fórmula (1) en donde X¹ y X² son, cada vez que aparecen, en forma independiente, un grupo CH o un átomo de nitrógeno, p es cero o un número entero de 1 a 3; cada R es independientemente H o halógeno; R¹ es un grupo de fórmula (2), en donde r es 0 o un número entero de 1 a 4; q es 0 o un número entero de 1 a 4; W¹ es un grupo divalente arileno o heteroarileno seleccionado entre A1 - A11 del grupo de fórmulas (3), en donde [1] es el punto de unión de W¹ al resto de la molécula y [2] es el punto de unión a -(CH₂)ʳ-; P está ausente o es un grupo divalente seleccionado entre O, S, SO, SO₂, CO, NR⁶, N(R⁶)(CH₂)ₙSO₂, N(R⁶)COO, N(R⁶)(CH₂)ₙC(O), N(R⁶)(CH₂)ₙO, SO₂N(R⁶), OC(O)N(R⁶) y C(O)N(R⁶), N(R⁶)C(O)N(R⁶); W² es H o se selecciona entre alquilo C₁₋₆, cicloalquilo C₃₋₈, heterocicloalquilo C₃₋₈, arilo, arilalquilo C₁₋₆ y heteroarilo; opcionalmente sustituido por uno o más sustituyentes independientemente seleccionados entre átomos de halógeno, -OH, oxo (=O), -SH, -NO₂, -CN, -CON(R⁶)₂, -C(O)R⁶, -NR⁶C(O)CH₃, -NH₂, -NHCOR⁶, -CO₂R⁶, -SO₂N(R⁶)₂, -NR⁶SO₂CH₃, alquilo C₁₋₆, haloalquilo C₁₋₆, alcoxi C₁₋₁₀, cicloalquilo C₃₋₈ y cicloalquilo C₃₋₆-carbonilo; n es, cada vez que aparece, en forma independiente, 0 o un número entero de 1 a 3; R⁶ es, cada vez que aparece, en forma independiente, H o se selecciona entre alquilo C₁₋₆, haloalquilo C₁₋₆, alquinilo C₂₋₆, alquenilo C₂₋₆, cicloalquilo C₃₋₈, heteroarilo y arilo opcionalmente sustituidos por uno o más sustituyentes seleccionados entre átomos de halógeno, -OH, oxo (=O), -SH, -NO₂, -CN, -CONH₂, -COOH, alquilo C₁₋₁₀ y alcoxi C₁₋₁₀; B es un grupo de fórmula R²R³N-alquilo C₁₋₆, opcionalmente sustituido por uno o más grupos seleccionados entre hidroxilo, alquilo C₁₋₆ e hidroxialquilo C₁₋₆; en donde R² y R³, iguales o diferentes, son H o se seleccionan entre alquilo C₁₋₆, hidroxialquilo C₁₋₆, o B es un grupo de fórmula R⁴R³N-alquilo C₁₋₆, en donde R³ es H, o se selecciona entre alquilo C₁₋₆, hidroxialquilo C₁₋₆ y R⁴ es un grupo alquilo divalente -(CH₂)ₛ-, en donde s es un número entero de 1 a 3, donde dicho grupo alquilo divalente está conectado al átomo de carbono en posición orto en el anillo adyacente para formar un anillo heterocíclico, preferentemente, un anillo heterocíclico de 4 a 10 miembros, fusionado con el anillo adyacente, en donde dicho anillo heterocíclico a su vez está opcionalmente sustituido con uno o más grupos seleccionados entre alquilo C₁₋₆, hidroxialquilo C₁₋₆; y sales y solvatos farmacéuticamente aceptables de los mismos.
ARP190101592A 2018-06-13 2019-06-10 Derivados de azaindol como inhibidores de rho-quinasa AR114926A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP18177556 2018-06-13

Publications (1)

Publication Number Publication Date
AR114926A1 true AR114926A1 (es) 2020-10-28

Family

ID=62631021

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP190101592A AR114926A1 (es) 2018-06-13 2019-06-10 Derivados de azaindol como inhibidores de rho-quinasa

Country Status (5)

Country Link
US (1) US20210253568A1 (es)
EP (1) EP3807273B1 (es)
AR (1) AR114926A1 (es)
MA (1) MA52891A (es)
WO (1) WO2019238628A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023552899A (ja) 2020-12-15 2023-12-19 キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ Ｒｈｏ－キナーゼ阻害剤としてのジヒドロフロピリジン誘導体
MX2023005865A (es) 2020-12-15 2023-06-05 Chiesi Farm Spa Derivados de dihidrofuropiridina como inhibidores de rho-cinasa.
MX2023005866A (es) 2020-12-15 2023-06-05 Chiesi Farm Spa Derivados de dihidrofuropiridina como inhibidores de rho-cinasa.
WO2023110700A1 (en) 2021-12-13 2023-06-22 Chiesi Farmaceutici S.P.A. Dihydrofuropyridine derivatives as rho-kinase inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5795977A (en) * 1989-09-15 1998-08-18 Metabasis Therapeutics, Inc. Water soluble adenosine kinase inhibitors
CA2503646C (en) 2002-10-28 2011-09-27 Bayer Healthcare Ag Heteroaryloxy-substituted phenylaminopyrimidines as rho-kinase inhibitors
DE102004017438A1 (de) 2004-04-08 2005-11-03 Bayer Healthcare Ag Hetaryloxy-substituierte Phenylaminopyrimidine
JP2008503492A (ja) 2004-06-17 2008-02-07 スミスクライン・ビーチャム・コーポレイション Ｒｈｏ−キナーゼの新規阻害剤
WO2009079008A1 (en) 2007-12-19 2009-06-25 Yangbo Feng Benzopyrans and analogs as rho kinase inhibitors
EP2331507A2 (en) 2008-09-18 2011-06-15 Astellas Pharma Inc. Heterocyclic carboxamide compounds
WO2012007539A1 (en) 2010-07-14 2012-01-19 Novartis Ag Ip receptor agonist heterocyclic compounds
HUE033962T2 (en) 2013-01-29 2018-01-29 Redx Pharma Plc Pyridine derivatives as soft rock (RHO kinase) inhibitors
EP3573987B1 (en) * 2017-01-30 2021-03-10 Chiesi Farmaceutici S.p.A. Tyrosine amide derivatives as rho- kinase inhibitors

Also Published As

Publication number Publication date
EP3807273A1 (en) 2021-04-21
MA52891A (fr) 2021-04-28
EP3807273B1 (en) 2022-08-03
WO2019238628A1 (en) 2019-12-19
US20210253568A1 (en) 2021-08-19

Similar Documents

Publication Publication Date Title
AR114926A1 (es) Derivados de azaindol como inhibidores de rho-quinasa
AR116109A1 (es) Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
AR092742A1 (es) Piridinonas antifibroticas
AR091981A1 (es) Dihidropiridona p1 como inhibidores del factor xia
AR094929A1 (es) Derivados de fenilpirazol como inhibidores potentes de rock1 y rock2
AR116913A1 (es) Inhibidores de apol1 y sus métodos de uso
AR088023A1 (es) COMPUESTOS CON ACTIVIDAD ANTAGONISTA DE LOS RECEPTORES MUSCARINICOS Y ACTIVIDAD AGONISTA DEL RECEPTOR b2 ADRENERGICO
AR094299A1 (es) Derivados de ftalazin-1(2h)-ona sustituidos
AR109650A1 (es) Compuestos de heteroarilcarboxamida como inhibidores de ripk2
AR101692A1 (es) Compuestos y métodos para inhibir histonas demetilasas
AR103833A1 (es) Compuestos bicíclicos de sulfonamida cetona
AR099379A1 (es) Compuestos tricíclicos como agentes antineoplásicos
AR089865A1 (es) Derivados de bencimidazol e imidazopiridinas como moduladores de canales de sodio
CO6251243A2 (es) Nuevos inhibidores macrocíclicos de la replicación del virus de hepatitis c
AR103990A1 (es) Ureas cíclicas como inhibidoras de rock
AR106595A1 (es) COMPUESTOS HETEROCÍCLICOS COMO INHIBIDORES DE PI3K-g
AR108185A1 (es) Amidas terciarias y método para su uso
AR095351A1 (es) Inhibidores de histona desacetilasa (hdac)
AR103742A1 (es) Derivados de trifluorometilpropanamida
AR098621A1 (es) Derivados de heteroarilo
AR106297A1 (es) Compuestos macrocíclicos modificados como inhibidores selectivos de la quinasa cdk9
AR061993A1 (es) Bencilaminas, un proceso para su produccion y su uso como agentes anti-inflamatorios
AR119792A1 (es) Derivados de pirazolo[4,3-c]piridina y composiciones farmacéuticas para el tratamiento de patologías inflamatorias
AR106185A1 (es) Compuestos macrocíclicos de sulfondiimina
AR109651A1 (es) Compuestos de piridina y pirazina como inhibidores de ripk2

Legal Events

Date Code Title Description
FB Suspension of granting procedure